» Articles » PMID: 26396921

Mutations of the Human Interferon Alpha-2b (hIFNα-2b) Gene in Cancer Patients Receiving Radiotherapy

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2015 Sep 24
PMID 26396921
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

This research aimed to find out the impact of ionizing radiations on the hIFNα-2b gene of radiotherapy treated cancer patients. The gene hIFNα-2b synthesizes a protein which is an important anticancerous and antiviral protein. The cancer patients (breast, lung, thyroid, oral and prostate) who were undergoing a radiotherapy treatment were selected. A molecular analysis was performed for DNA isolation and gene amplification through PCR, to identify gene mutations. Further, by bioinformatics tools we concluded that how mutations identified in gene sequences have led to the alterations in the hINFα-2b protein in radiotherapy receiving cancer patients. The 32% mutations in the hINFα-2b gene were identified and all were frameshift mutations. Radiotherapy can impact the immune system and cancer patients may modulate their immunity. Understaning the mechanisms of radiotherapy-elicited immune response may be helpful in the development of those therapeutic interventions that can enhance the efficacy of radiotherapy.

Citing Articles

A visualization analysis of immune-related adverse reactions in pulmonary carcinoma.

Gong Y, Kang J, Wang M, Firdaus Mohd Hayati M, Wah Goh L, Bin Syed Abdul Rahim S Hum Vaccin Immunother. 2024; 20(1):2429237.

PMID: 39588915 PMC: 11601054. DOI: 10.1080/21645515.2024.2429237.


Application of Nanoparticles in the Diagnosis and Treatment of Colorectal Cancer.

Song Q, Zheng Y, Zhong G, Wang S, He C, Li M Anticancer Agents Med Chem. 2024; 24(18):1305-1326.

PMID: 39129164 PMC: 11497148. DOI: 10.2174/0118715206323900240807110122.

References
1.
Ningrum R . Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo). 2014; 2014:970315. PMC: 3967813. DOI: 10.1155/2014/970315. View

2.
Vanpouille-Box C, Hindre F . Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity. Front Oncol. 2012; 2:136. PMC: 3467457. DOI: 10.3389/fonc.2012.00136. View

3.
Murray L, Henry A, Hoskin P, Siebert F, Venselaar J . Second primary cancers after radiation for prostate cancer: a review of data from planning studies. Radiat Oncol. 2013; 8:172. PMC: 3724744. DOI: 10.1186/1748-717X-8-172. View

4.
Mozdarani H . Biological complexities in radiation carcinogenesis and cancer radiotherapy: impact of new biological paradigms. Genes (Basel). 2014; 3(1):90-114. PMC: 3899963. DOI: 10.3390/genes3010090. View

5.
Kwilas A, Donahue R, Bernstein M, Hodge J . In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol. 2012; 2:104. PMC: 3434425. DOI: 10.3389/fonc.2012.00104. View